Logo-uniQure-MS-Word_Orange.jpg
uniQure Provides Update on Dose-Confirmation Study of AMT-061 in Patients with Hemophilia B
24 sept. 2018 07h00 HE | uniQure Inc.
~ Third patient treated in Phase IIb study ~ ~ Topline data expected to be available before the end of 2018 ~ LEXINGTON, Mass and AMSTERDAM, the Netherlands, Sept. 24, 2018 (GLOBE NEWSWIRE) --...